<DOC>
	<DOC>NCT00964574</DOC>
	<brief_summary>Primary Objective: To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients Secondary Objective: To evaluate the insulin glulisine doses To assess the patient satisfaction</brief_summary>
	<brief_title>Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients with type 1 diabetes mellitus who need insulin basal+ bolus regimen 6.5 &lt;=HbA1c &lt;= 11% at visit 1 BMI &lt;35 kg/mÂ² Provision of signed and dated informed consent prior to any study procedures Ability and willingness to complete study diaries and questionnaires Demonstrated ability to use the selfglucosemonitoring device, and to selfinject insulin A negative pregnancy test for all females of childbearing potential. Exclusion criteria: Hypersensitivity to insulin Glulisine, insulin Glargine or one of their excipients Pregnant women Active proliferative diabetic retinopathy Impaired hepatic or renal function The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>